For 260 pneumococcal and 266 staphylococcal strains, ranbezolid MICs ranged from <0.06 to 4 g/ml. The MICs for pneumococci were similar irrespective of the strains' ␤-lactam, macrolide, or quinolone susceptibilities, and ranbezolid MICs for coagulase-negative staphylococci were lower than those for Staphylococcus aureus. Ranbezolid was bacteriostatic against pneumococci. Ranbezolid MICs were similar to or lower than those of linezolid. Vancomycin and quinupristin-dalfopristin were also very active.
The incidence of pneumococci being resistant to penicillin G and other ␤-lactams and non-␤-lactams has increased worldwide at an alarming rate, including in the United States (1, 5, 9) . There is an urgent need for oral compounds for outpatient treatment of respiratory tract infections caused by resistant pneumococci (1, 5, 8) . The emergence of methicillin-and quinolone-intermediate, and recently glycopeptide-intermediate, staphylococci, as well as the propensity of these organisms to cause serious systemic infections in immunocompromised hosts, also necessitates other therapeutic modalities (7, 12, 21) .
The MICs of linezolid, an oxazolidinone which has been available clinically for the past few years, for pneumococci and staphylococci range between 0.5 and 4 g/ml, irrespective of the organisms' resistance to other agents (2-4, 6, 10, 15, 18) . Ranbezolid (RBX 7644; Ranbaxy Research Laboratories, New Delhi, India) is a new parenteral oxazolidinone with enhanced activity against gram-positive aerobes and gram-positive and gram-negative anaerobes.
The present study compared (i) the antipneumococcal activity of ranbezolid with those of linezolid, vancomycin, teicoplanin, quinupristin-dalfopristin, amoxicillin-clavulanate, ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin, and erythromycin by using MIC and time-kill studies and (ii) the antistaphylococcal activity of ranbezolid with those of linezolid, vancomycin, teicoplanin, and quinupristin-dalfopristin by using an MIC study.
The pneumococci tested comprised 89 penicillin-susceptible, 89 penicillin-intermediate, and 82 penicillin-resistant strains. Of these, 107 were erythromycin resistant. Twenty-six strains were quinolone resistant (levofloxacin MICs of Ն8 g/ml). For time-kill studies, 12 penicillin-susceptible, -intermediate, and -resistant strains (four of each), including six macrolide-resistant and two quinolone-resistant strains, were tested. Sixtyeight methicillin-resistant and 65 methicillin-susceptible Staphylococcus aureus strains and 69 methicillin-resistant and 64 methicillin-susceptible coagulase-negative staphylococci were examined.
Ranbezolid susceptibility powder was obtained from Ranbaxy Research Laboratories. Other antimicrobials were obtained from their respective manufacturers. For testing with pneumococci, agar dilution was performed by using MuellerHinton agar (BBL Microbiology Systems, Cockeysville, Md.) supplemented with 5% sheep blood (11) . Methicillin MIC plates for staphylococci were incubated for a full 24 h (11).
For time-kill studies, tubes containing 5 ml of cation-adjusted Mueller-Hinton broth (Difco) plus 5% lysed horse blood with doubling antibiotic concentrations were inoculated with 5 ϫ 10 5 to 5 ϫ 10 6 CFU/ml and incubated at 35°C in a shaking water bath. The methods employed in this study have been described previously (13, 19, 20) .
Time-kill assays were analyzed by determining the number of strains which yielded a change in log 10 CFU per milliliter of Ϫ1, Ϫ2, and Ϫ3 at 0, 3, 6, 12, and 24 h compared with the counts at time zero. Antimicrobials were considered bactericidal at the lowest concentration that reduced the original inoculum by Ն3 log 10 CFU/ml (99.9%) at each of the time periods, and they were considered bacteriostatic if the inoculum was reduced by 0 to Ͻ3 log 10 CFU/ml. The problem of bacterial carryover was addressed by dilution as described previously (13, 19, 20) . For erythromycin time-kill testing, only strains for which erythromycin MICs were Յ4.0 g/ml were tested.
Results of agar dilution MIC testing with strains classified by penicillin susceptibility are summarized in Table 1 . Ranbezolid MICs (range, 0.06 to 2.0 g/ml; MIC at which 50% of isolates tested are inhibited [MIC 50 ], 0.5 g/ml; MIC at which 90% of isolates tested are inhibited [MIC 90 ], 1.0 g/ml) were usually 2 to 3 dilutions lower than those of linezolid (range, 0.25 to 4.0 g/ml; MIC 50 , 1.0 g/ml; MIC 90 , 2.0 g/ml) against all strains. All strains were also susceptible to vancomycin (MICs, 0.125 to 0.5 g/ml), teicoplanin (MICs, Յ0.016 to 0.125 g/ml), and quinupristin-dalfopristin (MICs, 0.125 to 1.0 g/ml). The MICs of ␤-lactams and macrolides increased with those of penicillin G. The results for all drugs tested, except penicillin G and amoxicillin-clavulanate, were similar when strains were analyzed according to erythromycin susceptibility. Moxifloxacin yielded the lowest quinolone MICs against quinolone-susceptible and -resistant strains.
The results of time-kill analysis are presented in Table 2 . Ranbezolid and linezolid were mainly bacteriostatic, although bactericidal activity (99.9% killing) was detected against nine strains at four times the MIC after 24 h, with slower killing at earlier time periods. Vancomycin, teicoplanin, quinupristindalfopristin, amoxicillin-clavulanate, ciprofloxacin, gatifloxacin, and moxifloxacin were bactericidal against 11 of the 12 strains tested at the MIC after 24 h. Quinupristin-dalfopristin had the best kill kinetics of all drugs tested, with bactericidal activity against 10 of the 12 strains tested at two times the MIC after 3 h and against all 12 strains at two times the MIC after 24 h. Erythromycin was bactericidal against 8 of 9 erythromycin strains, with MICs of Յ4.0 g/ml at two times the MIC after 24 h. Regrowth was rarely found.
The MICs for staphylococci are listed in Tables 3 and 4 . The MIC 50 and MIC 90 of ranbezolid against S. aureus were 2 and 2 g/ml, respectively. By contrast, ranbezolid MICs against coagulase-negative strains were lower, with an MIC 50 of 0.125 g/ml and an MIC 90 of 1 g/ml. Linezolid MICs, especially against coagulase-negative strains, were often 1 to 2 dilutions higher than those of ranbezolid. Vancomycin MICs were low against all strains, but teicoplanin was much less active against coagulase-negative strains. Quinupristin-dalfopristin was equally active against all strains. The lower ranbezolid MICs for The results of the present study confirm the recently reported low MICs of ranbezolid against pneumococci and staphylococci (see above-cited abstracts). As is the case with other oxazolidinones (4), ranbezolid was bacteriostatic against most strains tested.
The results of MIC and time-kill studies of other compounds tested against pneumococci are similar to those described previously, with quinupristin-dalfopristin having the most rapid bactericidal activity, followed by quinolones, ␤-lactams, and macrolides (2, 3, 6, 9, 10, (13) (14) (15) (16) (17) (18) (19) (20) .
The results of this study indicate a potential role for ranbezolid in the treatment of pneumococcal and staphylococcal infections. However, interpretation of these in vitro results must be complemented by toxicity and pharmacokinetic-pharmacodynamic studies before the drug can be recommended for clinical testing. 
